力诺药包: 关于变更部分募集资金用途的公告

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]